National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016)
1Criteria for eligibility for drugs for the treatment of chronic hepatitis C
Start here
Get a plain-English read of 1
Turn the raw legal text into a practical explanation grounded in National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016).
1 Criteria for eligibility for drugs for the treatment of chronic hepatitis C
The criteria for patient eligibility for drugs for the treatment of chronic hepatitis C are that:
(1) the patient is 18 years or older; and
(2) the patient has been assessed in accordance with paragraph 2 of this Part; and
(3) the patient is:
- treated by a medical practitioner who is experienced in the treatment of patients with chronic hepatitis C infection and is:
- a gastroenterologist; or
- a hepatologist; or
- an infectious diseases physician; or
- treated in consultation with a medical practitioner who is experienced in the treatment of patients with chronic hepatitis C infection and who is:
- a gastroenterologist; or
- a hepatologist; or
- an infectious diseases physician